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INTRODUCTION
Intra-abdominal tumor is mostly associated with
ovarian malignancy. It is found in approximately
8% of all gynecological malignant tumor at all age,
but 60% is found in the women of more than 50
years old, 30% in reproductive age, while the re-
maining is found in younger age.1,2 Recently, it is
expected that there have been more cases with his-
topatological characteristic between benign ovari-
an tumor and malignant ovarian tumor, which is
classified as borderline ovarian tumor, the treat-
ment of which has not been fully agreed on. It is
expected that approximately 9.2-20% of whole
ovarian malignancy is this type of tumor, with the
survival rate of 95% despite the fact that the re-
currence and mortality may occur in 10 to 20 years
later. This is because this type of tumor has the
ability to metastasize to the organs far beyond the
internal genitalia. In Indonesia, ovarian malignant
tumor is commonly found and is the third largest
cause of death after cervical malignant tumor and
breast cancer, while the five-years survival rate of
20-37%.1
Abstract
Objective: To understand the molecular profile by identifying the
mutation of KRAS and BRAF in borderline type ovarian tumor.
Method: In the study, we examined paraffin tissue sample from De-
partment of Pathology Anatomy, University of Indonesia/Dr. Cipto
Mangunkususmo Hospital, Jakarta, that was diagnosed as borderline
epithelial ovarian tumor. Seventeen samples were taken to Sandya
Laboratory in Bandung for examination of PCR BRAF exon 15 codon
600, and KRAS in exon 2 codon 12 and 13, as well as exon 3 codon
61.
Result: Mutation of KRAS occurred in 94% of subjects (serous bor-
derline 62.5%, mucinous bordeline 37.5%), of which 70.6% muta-
tion happened in exon 2 codon 12 (serous borderline 33.3%, muci-
nous borderline 66.7%), 52.9% mutation in exon 2 codon 13 (serous
borderline 33.3%, mucinous borderline 66.7%), and 76.5% muta-
tion in exon 3 codon 61 (serous borderline 30.8%, mucinous border-
line 69.2%). Mutation of BRAF occurred only in 47% of subjects, but
the results of Exact Fisher test showed that mutation in BRAF gave
significant result, while other variables did not give significant result
(p=0.009).
Conclusion: Molecular pathology in borderline ovarian tumor re-
lated with BRAF mutation is more likely to occur in serous border-
line type, while KRAS mutation is more likely to occur in mucinous
borderline type.
[Indones J Obstet Gynecol 2013; 37-2: 107-12]
Keywords: borderline ovarian tumor, BRAF, KRAS
Abstrak
Tujuan: Untuk mengetahui mutasi KRAS dan BRAF pada tumor ova-
rium type borderline.
Metode: Bahan penelitian adalah blok parafin jaringan yang berada
di Bagian Patologi Anatomi, FKUI/RSUPNCM Jakarta yang telah didi-
agnosis sebagai tumor ovarium tipe borderline. Tujuh belas sampel
dibawa ke Laborataorium Sandya di kota Bandung untuk dilakukan
pemeriksaan PCR BRAF Exon 15 Codon 600, dan KRAS pada Exon 2
codon 12 dan 13, serta exon 3 codon 61.
Hasil: Mutasi KRAS terjadi pada 94% sediaan (borderline serosum
62,5%, borderline musinosum 37,5%), dengan perincian mutasi pada
exon 2 codon 12 sebanyak 70,6% (borderline serosum 33,3%, border-
line musinosum 66,7%), mutasi exon 2 codon 13 sebanyak 52,9% (bor-
derline serosum 33,3%, borderline musinosum 66,7%), dan mutasi
pada exon 3 codon 61 sebanyak 76,5% (borderline serosum 30,8%,
borderline musinosum 69,2%). Mutasi BRAF terjadi hanya pada 47%
sediaan, tetapi hasil uji Eksak Fisher memperlihatkan bahwa mutasi
pada BRAF memperlihatkan hasil signifikan, sementara variabel yang
lainnya tidak memberikan hasil yang signifikan (p=0,009).
Kesimpulan: Tampak adanya kecenderungan pada tipe borderline
serosum lebih banyak terjadi mutasi pada BRAF, sedangkan pada tipe
borderline musinosum lebih banyak terjadi mutasi KRAS.
[Maj Obstet Ginekol Indones 2013; 37-2: 107-12]
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Identification and knowledge about the charac-
teristics of molecular change associated with car-
cinogenesis will facilitate the development of diag-
nostic test to detect early ovarian carcinoma and
to develop specific therapy that could block or
minimize the signals of tumor growth.3
Until now the pathogenesis of ovarian carcino-
ma is unknown. Likewise is the progressivity.4
Ovarian carcinoma is very heterogeneous, and pri-
mary it is classified on the basis of cellular types
into serous, mucinous, endometrioid, clear cell, and
Brenner (transitional). It is associated with the dif-
ference of epithelial types of women’s reproduc-
tion organ.5,6
Tumors in this category is further divided into
3 (three) groups, which are benign, malignant and
intermediate (borderline tumor), reflecting the
characteristics of the carcinoma. Borderline tumor
of mucinous and endometrioid type are frequently
associated with invasive carcinoma, but borderline
serous tumor is seldom associated with serous car-
cinoma.5 In further observation, the advancement
of molecular genetics studies has shown differen-
ces of frequency of mutation of p53 and KRAS in
serous carcinoma and in borderline tumor of se-
rous. This has made researchers conclude that pro-
bably serous borderline tumor is not related to
serous carcinoma.5-8 The unspecific characteristics
of borderline tumor are reflected in the word bor-
derline it self, implying ambiguous condition. Ba-
sed on the review of molecular and clinical pathol-
ogy studies, a model of tumor development is pro-
posed. In this model, epithelial tumor deriving
from ovarian surface is divided into two large cate-
gories: type I and type II based on the charac-
teristics of the pathogenesis. Type I tumors tend to
be low-grade tumor growing from borderline tu-
mors, while type II tumors are high grade tumors
where the precursor lesion is morphologically un-
identified and thus is called to have de novo deve-
lopment.9
These carcinogenesis model shows the correla-
tion between borderline tumors and invasive car-
cinoma and describes morphological and molecu-
lar structure that can be used to clarify the patho-
genesis of ovarian cancer.9
There are some specific molecular changes that
differentiate low grade and high grade carcinomas
such as the genetic mutation of BRAF and KRAS.
Cascade of RAS, RAF, MEK, ERK, and MAP play im-
portant role in transmitting growth signals to stem
cells. Oncogenic mutation of BRAF and KRAS show
activation of this type and help neoplastic transfor-
mation process.7,10-12 Mutation of BRAF and KRAS
seem to occur at very early phase of low grade
serous carcinoma growth as indicated by the mu-
tations in small atypical proliferative type serous
tumor.13,14
METHOD
In the study, we examined paraffin tissue sample
from Department of Pathology Anatomy, Universi-
ty of Indonesia/Dr.Cipto Mangunkususmo Hospital,
Jakarta, that was diagnosed as borderline epithelial
ovarian tumor. Seventeen samples were taken to
Sandya Laboratory in Bandung for examination of
PCR BRAF exon 15 codon 600, and KRAS in exon
2 codon 12 and 13, as well as exon 3 codon 61.
RESULTS
Results of Exact Fisher test show that there is no
significant correlation between results of anatomi-
cal pathology and patients’ characteristics. The re-
sults are presented in the following Table 1.
Table 1. Results between Characteristic and PA Examina-
tion Results.
Variable
Results of PA
Value p*)
Serous
(n=5)
Mucinous
(n=12)
Age (year): 1.0
• < 40 1 4
• 40 4 8
• Standard De-
viation (SD)
42.2 (13.9) 42.3 (14.5)
Parity: 0.319
• 0 3 3
• 1-3 2 7
• ≥ 4 0 2
Menopause Status: 1.0
• Yes 2 6
• No 3 6
Solid Part: 0.60
• Yes 4 7
• No 1 5
Ascites: 0.131
• Yes 4 4
• No 1 8
Remarks: *) based on Fisher Exact test
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Fisher Exact test results also show that of the
five independent variables, only mutation of BRAF
shows significant results, while other variables did
not give significant result. The results of the test
are presented in the following Table 2.
Table 2. Correlation between Mutation of KRAS and
BRAF and Results of Histopathology (HP) Examination.
Variable
Results of HP
Value p*)
Serous
(n=5)
Mucinous
(n=12)
Mutation of KRAS
Ex2Cod12:
1.0
• Positive 4 8
• Negative 1 4
Mutation of KRAS
Ex2Cod13:
1.0
• Positive 3 6
• Negative 2 6
Mutation of KRAS
Ex3Cod61:
1.0
• Positive 4 9
• Negative 1 3
Mutation of BRAF
Ex15Cod600:
0.009
• Positive 5 3
• Negative 0 9
Other Fisher Exact tests to identify the correla-
tion between mutation of BRAF and mutation of
KRAS show no significant correlation as presented
in the following Table 3.
Table 3. Correlation between Mutation of KRAS and BRAF in Epithelial and Borderline Type Ovarian Tumors.
Variable
Mutation of BRAF Ex15Cod600
Value p*)
Positive (n=8) Negative (n=9)
Mutation of KRAS Ex2Cod12: 0.294
• Positive 7 5
• Negative 1 4
Mutation of KRAS Ex2Cod13: 0.153
• Positive 6 3
• Negative 2 6
Mutation of KRAS Ex3Cod61: 0.576
• Positive 7 6
• Negative 1 3
Table 4. Correlation between RMI Score and Mutation of
BRAF and KRAS in Epithelial and Borderline Type Ovarian
Tumor.
Variable Score RMI*) Value p**)
BRAF Ex15Cod600: 0.321
• Positive (n=8) 391.2 (66.3-9764)
• Negative (n=9) 203.1 (23.3-2072.8)
KRAS Ex2Cod12: 0.160
• Positive (n=12) 256.2 (23.3-3104.8)
• Negative (n=5) 968.0 (203.1-9764)
KRAS Ex2Cod13: 0.423
• Positive (n=9) 351.6 (23.3-3104.8)
• Negative (n=8) 339.8 (131.6-9764)
KRAS Ex3Cod61: 0.871
• Positive (n=13) 351.6 (23.3-9764)
• Negative (n=4) 549.8 (88.6-3104.8)
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Mann-Whitney test was performed to identify
the correlation between the use of RMI score as a
method to identify the probability of malignancy
and the mutation of BRAF and KRAS show insig-
nificant correlation. But the higher the score of
RMI, the more likely the mutation of BRAF was to
be found while the lower the score of RMI, the
more likely of mutation of KRAS (Exon 2 Codon 12
and Exon 3 Codon 61) was to be found.
DISCUSSION
Behavior of borderline epithelial neoplasm is be-
tween benign and malignant. Complex aberration
is not found in borderline tumor and differences
between genetic aberration can be seen in border-
line tumor and invasive carcinoma, thus implies
that high grade invasive tumor occur from existing
borderline lesion. Peritoneal implant is found in
60% serous type borderline tumor but might be
found in cases without ovarian tumor.1,3
Kinase RAS-RAF-MEK-ERK-MAP path is fre-
quently affected in carcinoma; particularly oncogen
RAS play pivotal role in tumorigenesis. Mutation of
RAS first described in malignant melanoma, pulmo-
nary carcinoma and thyroid papillary. One of 3
proto-oncogen RAS shows mutation in 25% cases
of carcinoma; codon 12, 13 and 61 KRAS are
mostly affected. Mutation of KRAS shows constitu-
tive activation from protein with the increase ex-
change of GDP/GTP or decrease of GTPase protein
activity, that leads to the increase of cellular pro-
liferation. Mutation of KRAS and BRAF in noninva-
sive carcinoma and invasive ovarian has been re-
ported previously where mutation of KRAS is com-
monly found in ovarian tumor of mucinous
subtype and in borderline serous tumor, but not in
invasive serous carcinoma. Three codes of genes of
RAF for kinase cytoplasmic serine/threonine have
been regulated with the binding of RAS. Almost
90% of mutation of BRAF occurs upon or soon af-
ter activation of exon 15, that protect substrate
binding site.5,8
In more than 90% cases, mutation of BRAF oc-
cur as substitution of adenine (A) with thymidine
(T) in the position of nucleotida 1796, that con-
verts valine into glutamic acid in the position of
600 (V600E). Mutation of BRAF leads to activation
of ERK, and this promotes transition of G1/S in cel-
lular cycle regulation.5,8
In most mutation of BRAF (80-86%) in cancer
tranfersion of T>A occur in codon 600 that results
in substitution of glutamat to valin. This can in-
crease and change the process of phosphorilation
need in the process of activation of BRAF and in-
crease the signal needed in activation of MAPK (mi-
togen-activated protein kinase), MEK (Mitogen-ac-
tivated protein kinase kinase) and ERK (extracel-
lular signal-regulated kinase). Some other types of
mutations related to codon 600 and the neighbor-
ing codon in exon 15 has been identified. Most vari-
ations of mutation activate mitogen activated pro-
tein kinase kinase (MAPK kinase) that will disturb
the signal of activation from extracellular signal-
regulated kinase (ERK), but it is rare that the mu-
tation occur in CRAF and ERK that lead to section-
ing of path of MAPK kinase.9,13
Mutation of BRAF and KRAS is not always found
in similar tumor but the type of tumor show mu-
tation of KRAS and BRAF are identical. This sup-
ports the hypothesis that mutation of KRAS and
BRAF is equivalent for the gumorigenic effect.
This study found mutation of BRAF in 47% of
the samples and mutation of KRAS in 94% (serous
borderline 62.5%, mucinous borderline 37.5%),
with 70.6% mutation of exon 2 codon 12 (serous
borderline 33.3%, mucinous borderline 66.7%),
52.9% mutation of exon 2 codon 13 (serous bor-
derline 33.3%, mucinous borderline 66.7%), and
76.6% mutation of exon 3 codon 61 (serous bor-
derline 30.8%, mucinous borderline 69.2%). In the
study by Mayr D, it was found that mutation of
KRAS or BRAF is commonly found in borderline
serous and mucinous tumors. Mutation of BRAF is
found in 30% of all borderline serous tumors, but
in subjects with invasive mucinous tumor, there
was only one case found and in subjects with
serous carcinoma, there was no mutation found.
Finding of mutation of BRAF in a carcinoma en-
dometrioid type (K600N) and a clear-cell carci-
noma (S615F) need further studies at larger scales.
Mutation of KRAS was found in almost 50% of
mucinous and more than 20% of serous type of
borderline tumor but is rare in any invasive carci-
noma subtype. The correlation between mutation
of BRAF and KRAS in similar cancer type shows
activation of RAS-RAF-MAPK-MEK-ERK kinase
path can be achieved by activating different muta-
tion activation.15
Borderline ovarian tumor of serous and muci-
nous, may represent pathological correlation bet-
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ween benign and invasive carcinomas, but they
seem to be heterogeneous groups. Results of Fisher
exact test showed that of the five independent vari-
ables, only mutation of BRAF show significant re-
sult (p=0.009), while others did not give any sig-
nificant result. Therefore, it seems examination in
BRAF may be more prioritized than examination
in KRAS. Results of other Exact Fisher tests showed
(Table 2), that there was no significant correlation
between mutation of KRAS and BRAF and the
pathological type. However, there is a tendency in
serous borderline type more mutations of BRAF
were found, while in mucinous borderline type
more mutation of KRAS was found.
RMI scores as a method to estimate malignancy is
a standard action in ovarian tumor. Results of Mann-
Whitney test in the study to identify the correlation
between the use of RMI score to see the possible ma-
lignancy with mutation of BRAF and KRAS show in-
significant correlation. However it is found that there
was a positive tendency in mutation of BRAF, where
the higher the score of RMI, the higher the probability
of mutation of BRAF and negative correlation with
KRAS, the lower the score of RMI the more probably
the mutation of KRAS (Exon 2 Codon 12 and Exon 3
Codon 61).
CONCLUSION
Mutation of KRAS occured in 94% of samples
(serous borderline 62.5%, mucinous borderline
37.5%), that is mutation of exon 2 codon 12 of
70.6% (serous borderline 33.3%, mucinous bor-
derline 66.7%), mutation of exon 2 codon 13 of
52.9% (serous borderline 33.3%, mucinous bor-
derline 66.7%), and mutation of exon 3 codon 61
of 76.5% (serous borderline 30.8%, borderline
mucinous 69.2%),
Mutation of BRAF occured in 47% of samples, but
results of Exact Fisher test showed that mutation of
BRAF showed significant results, while other vari-
ables did not give significant results.
There is no significant correlation between muta-
tion of KRAS and BRAF and pathological type. How-
ever, there is a tendency that in serous borderline
type there were more mutations of BRAF, while in
mucinous borderline type there were more muta-
tions of KRAS.
There was a positive tendency of mutation of
BRAF, where the higher the score of RMI, the
higher the probability of mutation of BRAF and
negative correlation with KRAS, the lower the
score of RMI the higher the probability of mutation
of KRAS (Exon 2 Codon 12 and Exon 3 Codon 61).
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